A new trading day began on Tuesday, with TransCode Therapeutics Inc (NASDAQ: RNAZ) stock price down -36.73% from the previous day of trading, before settling in for the closing price of $6.78. RNAZ’s price has ranged from $2.66 to $66.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 95.41%. With a float of $0.66 million, this company’s outstanding shares have now reached $0.70 million.
Let’s determine the extent of company efficiency that accounts for 10 employees. In terms of profitability, gross margin is 43.62%, operating margin of -1947.19%, and the pretax margin is -1981.89%.
TransCode Therapeutics Inc (RNAZ) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of TransCode Therapeutics Inc is 5.08%, while institutional ownership is 31.14%.
TransCode Therapeutics Inc (RNAZ) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 95.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 78.85% during the next five years compared to -28.81% drop over the previous five years of trading.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Trading Performance Indicators
Here are TransCode Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -265.83, a number that is poised to hit -105.93 in the next quarter and is forecasted to reach -144.21 in one year’s time.
Technical Analysis of TransCode Therapeutics Inc (RNAZ)
Looking closely at TransCode Therapeutics Inc (NASDAQ: RNAZ), its last 5-days average volume was 0.22 million, which is a drop from its year-to-date volume of 2.78 million. As of the previous 9 days, the stock’s Stochastic %D was 9.46%. Additionally, its Average True Range was 2.05.
During the past 100 days, TransCode Therapeutics Inc’s (RNAZ) raw stochastic average was set at 6.87%, which indicates a significant increase from 5.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 305.67% in the past 14 days, which was higher than the 209.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.28, while its 200-day Moving Average is $17.30. However, in the short run, TransCode Therapeutics Inc’s stock first resistance to watch stands at $6.18. Second resistance stands at $8.08. The third major resistance level sits at $9.31. If the price goes on to break the first support level at $3.06, it is likely to go to the next support level at $1.83.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Key Stats
With a market capitalization of 2.99 million, the company has a total of 696K Shares Outstanding. Currently, annual sales are 0 K while annual income is -18,550 K. The company’s previous quarter sales were 0 K while its latest quarter income was -2,320 K.
